Molecular Cancer Therapeutics · 2023 · 19 citations · 61 references
MedicineImmunologyOncologyCancer ImmunologyImmunizationImmunotherapyCancer ImmunotherapyCancer VaccinesCombination ImmunotherapyGlioblastomaTherapeutic VaccinesVaccine-based ImmunotherapyAdaptive Antitumor ImmunityAdministration Of Monoclonal AntibodiesGlioblastoma ImmunotherapyGlioblastoma Targeted TherapyMonoclonal Antibodies In CancerRna Vaccine ImmunotherapyTumor Antigen VaccinesTumor-associated Antigen Vaccines
Glioblastoma (GBM), also known as grade IV astrocytoma, is the most common and deadly type of central nervous system malignancy in adults. Despite significant breakthroughs in current GBM treatments such as surgery, radiotherapy, and chemotherapy, the prognosis for late-stage glioblastoma remains bleak due to tumor recurrence following surgical resection. The poor prognosis highlights the evident and pressing need for more efficient and targeted treatment. Vaccination has successfully treated patients with advanced colorectal and lung cancer. Therefore, the potential value of using tumor vaccines in treating glioblastoma is increasingly discussed as a monotherapy or in combination with other cellular immunotherapies. Cancer vaccination includes both passive administration of monoclonal antibodies and active vaccination procedures to activate, boost, or bias antitumor immunity against cancer cells. This article focuses on active immunotherapy with peptide, genetic (DNA, mRNA), and cell-based vaccines in treating GBM and reviews the various treatment approaches currently being tested. Although the ease of synthesis, relative safety, and ability to elicit tumor-specific immune responses have made these vaccines an invaluable tool for cancer treatment, more extensive cohort studies and better guidelines are needed to improve the efficacy of these vaccines in anti-GBM therapy.
61
<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas
Hai Yan, D. Williams Parsons, Genglin Jin et al. · New England Journal of Medicine · 2009 · 5.9K citations · Full text
Profiling Tumor Infiltrating Immune Cells with CIBERSORT
Binbin Chen, Michael S. Khodadoust, Chih Long Liu et al. · Methods in molecular biology · 2018 · 4.2K citations · Full text
Medicine, Immunology, Oncology +12
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Veronika Groh, Jennifer D. Wu, Cassian Yee et al. · Nature · 2002 · 1.6K citations
Life Sciences, Immunology, Oncology +15